Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Jul 15 · above the Ichimoku cloud · RSI 63 · MACD above its signal
None of the 29 investors followed here reported a position in 1681.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1681.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 16, 2025 | An (Meng)Chief Executive Officer | Acquisition at price 1.54 per share. | 50K | $76.83K |
| Jul 14, 2025 | An (Meng)Chief Executive Officer | Acquisition at price 1.47 per share. | 136K | $200.10K |
| Jul 10, 2025 | An (Meng)Chief Executive Officer | Acquisition at price 1.45 per share. | 251K | $363.22K |
| Jul 9, 2025 | An (Meng)Chief Executive Officer | Acquisition at price 1.42 per share. | 27K | $38.45K |
| May 25, 2025 | An (Meng)Chief Executive Officer | — | 197.32M | — |
| Apr 22, 2025 | An (Meng)Chief Executive Officer | — | 10.41M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.0 | -0.4 | -7.4 | -2.6 | -12.6 | -11.3 | 8.8 | -1.2 | 9.7 | 1.1 | −3.7% | ||
| 2025 | -3.7 | 2.2 | 15.5 | 0.2 | 14.7 | 6.6 | 21.7 | 8.1 | 14.7 | -12.0 | -1.3 | 5.1 | +91.6% |
| 2024 | 11.5 | 6.8 | -1.4 | 4.5 | 13.8 | -16.5 | 0.7 | 2.1 | 24.3 | 16.3 | -2.3 | 0.6 | +70.4% |
| 2023 | 2.0 | 7.7 | 7.6 | 6.3 | -5.9 | 10.6 | 7.5 | -9.1 | -1.7 | -9.6 | -2.0 | 5.8 | +17.8% |
| 2022 | -13.2 | -2.6 | 2.7 | 21.2 | -12.1 | 2.7 | 2.9 | -6.3 | -16.6 | -12.5 | 14.6 | 20.2 | −8.0% |
| 2021 | 3.2 | 2.5 | 22.9 | 14.4 | 25.0 | -11.8 | -9.3 | -20.2 | -3.5 | -5.1 | 10.1 | 18.9 | +42.4% |
| 2020 | -13.8 | -4.8 | -7.9 | 14.0 | -17.5 | -3.0 | -7.2 | 10.4 | 1.8 | -8.7 | 1.0 | 0.3 | −33.4% |
| 2019 | 29.7 | 1.9 | -4.2 | -4.5 | -4.9 | 2.3 | -11.0 | -10.3 | 1.4 | 8.5 | -6.8 | 5.9 | +2.0% |
| 2018 | 24.7 | -7.2 | 1.7 | 1.9 | 3.8 | -16.7 | -18.5 | 15.4 | -9.6 | -13.0 | 6.8 | -21.6 | −35.7% |
| 2017 | -1.8 | 14.0 | 4.2 | 16.9 | 7.2 | 7.4 | 4.5 | 0.2 | 3.8 | 9.1 | 0.3 | -1.7 | +83.4% |
| 2016 | -15.9 | -4.2 | -1.5 | -5.7 | 5.0 | -1.0 | -2.8 | 25.7 | -6.6 | 0.2 | -5.3 | -10.0 | −24.2% |
| 2015 | 3.9 | -7.2 | -4.4 | 15.0 | -5.2 | -5.1 | 3.2 | -10.1 | -9.1 | -3.2 | 5.0 | 6.3 | −13.0% |
| 2014 | 15.5 | 13.6 | -5.5 | -6.7 | 9.6 | -5.4 | -4.3 | 9.4 | 11.8 | -1.2 | -9.8 | -3.5 | +20.9% |
| 2013 | — |
Buy / hold / sell counts
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
No recent headlines.